A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

Kyeong Lee; Hwan Mook Kim

doi:10.1007/s12272-011-1021-3

A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

Kyeong Lee
, Hwan Mook Kim

Department of Pharmacy

Gachon University

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Abstract

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.

Original language	English
Pages (from-to)	1583-1585
Number of pages	3
Journal	Archives of Pharmacal Research
Volume	34
Issue number	10
DOIs	https://doi.org/10.1007/s12272-011-1021-3
State	Published - Oct 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s12272-011-1021-3

Cite this

@article{b26657a141ae4b2c816b018df60d66e5,

title = "A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor",

abstract = "Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.",

author = "Kyeong Lee and Kim, \{Hwan Mook\}",

year = "2011",

month = oct,

doi = "10.1007/s12272-011-1021-3",

language = "English",

volume = "34",

pages = "1583--1585",

journal = "Archives of Pharmacal Research",

issn = "0253-6269",

publisher = "Pharmaceutical Society of Korea",

number = "10",

}

TY - JOUR

T1 - A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

AU - Lee, Kyeong

AU - Kim, Hwan Mook

PY - 2011/10

Y1 - 2011/10

N2 - Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.

AB - Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.

UR - https://www.scopus.com/pages/publications/82055185047

U2 - 10.1007/s12272-011-1021-3

DO - 10.1007/s12272-011-1021-3

M3 - Article

C2 - 22076756

AN - SCOPUS:82055185047

SN - 0253-6269

VL - 34

SP - 1583

EP - 1585

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

IS - 10

ER -

A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this